Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

CAH US Equity

Cardinal Health IncConsumer Discretionary · Wholesale-Drugs, Proprietaries & Druggists' Sundries · CIK 721371 · FY ends Jun 30
$234.98
-0.68 (-0.29%)
USD · as of 2026-08-18 · marketstack
1 registered study · 0 active

Studies where CAH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional

Held by 23 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, Man Group plc, D. E. Shaw & Co., Inc., RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, +18 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 3 executive

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Design Validation Hemodynamic Study of New Kendall SCD SmartFlow Compression SystemNCT05945186Blood VelocityOpen-label · OtherNot applicableUnknown statusDevice: Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)Hemodynamics19Oct 20232023-07-14

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19